These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23133319)

  • 1. Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer.
    Deshpande HA; Sheth K; Sosa JA; Roman S
    Clin Med Insights Oncol; 2012; 6():355-62. PubMed ID: 23133319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of vandetanib in the management of medullary thyroid cancer.
    Brassard M; Rondeau G
    Biologics; 2012; 6():59-66. PubMed ID: 22500115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating medullary thyroid cancer in the age of targeted therapy.
    Cabanillas ME; Hu MI; Jimenez C; Grubbs EG; Cote GJ
    Int J Endocr Oncol; 2014; 1(2):203-216. PubMed ID: 25908961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
    Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vandetanib for the treatment of metastatic medullary thyroid cancer.
    Degrauwe N; Sosa JA; Roman S; Deshpande HA
    Clin Med Insights Oncol; 2012; 6():243-52. PubMed ID: 22723734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hereditary medullary thyroid carcinoma.
    Pappa T; Alevizaki M
    Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances and controversies in the management of medullary thyroid carcinoma.
    Maia AL; Wajner SM; Vargas CV
    Curr Opin Oncol; 2017 Jan; 29(1):25-32. PubMed ID: 27792051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.
    Giunti S; Antonelli A; Amorosi A; Santarpia L
    Int J Endocrinol; 2013; 2013():803171. PubMed ID: 23509459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer.
    Pozo K; Zahler S; Ishimatsu K; Carter AM; Telange R; Tan C; Wang S; Pfragner R; Fujimoto J; Grubbs EG; Takahashi M; Oltmann SC; Bibb JA
    Oncotarget; 2018 Dec; 9(102):37662-37675. PubMed ID: 30701022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib-treated advanced medullary thyroid carcinoma: a case report.
    Chen K; Gao Y; Shi F; Cao G; Bao J
    Onco Targets Ther; 2018; 11():459-463. PubMed ID: 29403290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
    Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
    Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapy for Medullary Thyroid Cancer: A Review.
    Priya SR; Dravid CS; Digumarti R; Dandekar M
    Front Oncol; 2017; 7():238. PubMed ID: 29057215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies in thyroid cancer: an extensive review of the literature.
    Bikas A; Vachhani S; Jensen K; Vasko V; Burman KD
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1299-1313. PubMed ID: 27367142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer.
    Deshpande H; Roman S; Thumar J; Sosa JA
    Clin Med Insights Oncol; 2011; 5():213-21. PubMed ID: 21836817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs for medullary thyroid cancer: new promises?
    Spitzweg C; Morris JC; Bible KC
    Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer - An Evolving Paradigm.
    Jarzab B; Krajewska J
    Eur Endocrinol; 2014 Aug; 10(2):145-150. PubMed ID: 29872479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies.
    Gómez K; Varghese J; Jiménez C
    J Thyroid Res; 2011; 2011():815826. PubMed ID: 21687607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.
    Lodish M; Gkourogianni A; Bornstein E; Sinaii N; Fox E; Chuk M; Marcus L; Akshintala S; Balis F; Widemann B; Stratakis CA
    Int J Pediatr Endocrinol; 2015; 2015(1):3. PubMed ID: 25972901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.